Inhibikase Therapeutics (IKT) Assets Average (2021 - 2025)
Inhibikase Therapeutics (IKT) has disclosed Assets Average for 5 consecutive years, with $84.2 million as the latest value for Q3 2025.
- On a quarterly basis, Assets Average rose 1175.76% to $84.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $84.2 million, a 1175.76% increase, with the full-year FY2024 number at $56.6 million, up 186.76% from a year prior.
- Assets Average was $84.2 million for Q3 2025 at Inhibikase Therapeutics, down from $91.6 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $96.4 million in Q1 2025 to a low of $6.6 million in Q3 2024.
- A 5-year average of $37.4 million and a median of $30.5 million in 2021 define the central range for Assets Average.
- Peak YoY movement for Assets Average: plummeted 67.18% in 2024, then skyrocketed 1175.76% in 2025.
- Inhibikase Therapeutics' Assets Average stood at $44.2 million in 2021, then plummeted by 39.42% to $26.8 million in 2022, then plummeted by 39.48% to $16.2 million in 2023, then soared by 217.95% to $51.5 million in 2024, then skyrocketed by 63.58% to $84.2 million in 2025.
- Per Business Quant, the three most recent readings for IKT's Assets Average are $84.2 million (Q3 2025), $91.6 million (Q2 2025), and $96.4 million (Q1 2025).